xCT as a Predictor for Survival in a Population-Based Cohort of Head and Neck Squamous Cell Carcinoma

被引:0
作者
Nissi, Linda [1 ,2 ,3 ]
Tuominen, Sanni [4 ,5 ]
Routila, Johannes [3 ,6 ]
Huusko, Teemu [3 ,6 ]
Ketonen, Petra [4 ,5 ]
Sundvall, Maria [1 ,2 ,3 ,7 ]
Leivo, Ilmo [3 ,8 ]
Irjala, Heikki [3 ,6 ]
Minn, Heikki [1 ,2 ,3 ]
Gronroos, Tove J. [1 ,4 ,5 ]
Ventela, Sami [6 ,9 ]
机构
[1] Turku Univ Hosp, Dept Oncol, Turku, Finland
[2] Turku Univ Hosp, FICAN West Canc Ctr, Turku, Finland
[3] Univ Turku, Turku, Finland
[4] Univ Turku, Preclin Imaging Turku PET Ctr, Turku, Finland
[5] Univ Turku, Med Res Lab, Turku, Finland
[6] Turku Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Turku, Finland
[7] Univ Turku, Inst Biomed, Canc Res Unit, Turku, Finland
[8] Turku Univ Hosp, Dept Pathol, Turku, Finland
[9] Univ Turku, Turku Biosci Ctr, Turku, Finland
关键词
CYSTEINE/GLUTAMATE TRANSPORTER; CISPLATIN RESISTANCE; CANCER-CELLS; FOLLOW-UP; FERROPTOSIS; BIOMARKER; SLC7A11; SULFASALAZINE; SUPPRESSION; RECURRENCE;
D O I
10.1002/cam4.70371
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: xCT, also known as SLC7A11 (solute carrier Family 7 Member 11), is a cystine/glutamate antiporter protein that mediates regulated cell death and antioxidant defense. The aim of this study was to investigate the effect of xCT on the outcome of patients diagnosed with new head and neck squamous cell carcinoma (HNSCC). Methods: This retrospective cohort study utilized a population-based dataset, comprising all patients (n = 1033) diagnosed with new HNSCC during 2005-2015 in a population of 697,000 people. All patients (n = 585) with a tumor tissue sample available for immunohistochemical (IHC) staining were included. The follow-up rates were 97% and 81% at 3 and 5 years, respectively. Also, the specificity of the anti-xCT antibody was validated. Results: The expression level and prognostic significance of xCT were strongly dependent on tumor location. In oropharyngeal squamous cell carcinoma (OPSCC) patients, xCT expression was a significant prognostic factor for 5-year overall survival (OAS) (HR: 2.71; 95% CI 1.67-4.39; p < 0.001), disease-specific survival (DSS) (HR: 2.58; 95% CI 1.47-4.54; p = 0.001), and disease-free survival (DFS) (HR: 2.69; 95% CI 1.55-4.64; p < 0.001). Five-year survival rates for OPSCC patients with high and low levels of xCT were OAS 34% versus 62%; DSS 51% versus 73%; DFS 43% versus 73%, respectively. According to a multivariate model adjusted for age, T-class, nodal positivity, and tobacco consumption, xCT was an independent prognostic factor for 3-year survival, in which it outperformed p16 IHC. Similar associations were not observed in squamous cell carcinomas of oral cavity or larynx. Regarding treatment modalities, xCT was most predictive in HNSCC patients who received radiotherapy. Conclusions: High xCT expression was associated with poor prognosis in OPSCC. Our findings suggest that joint analysis of xCT and p16 may add significant value in OPSCC treatment stratification.
引用
收藏
页数:10
相关论文
共 56 条
[11]   Pattern of and survival following loco-regional and distant recurrence in patients with HPV plus and HPV- oropharyngeal squamous cell carcinoma: A population-based study [J].
Gronhoj, Christian ;
Jakobsen, Kathrine Kronberg ;
Jensen, David H. ;
Rasmussen, Jacob ;
Andersen, Elo ;
Friborg, Jeppe ;
von Buchwald, Christian .
ORAL ONCOLOGY, 2018, 83 :127-133
[12]   Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition [J].
Hangauer, Matthew J. ;
Viswanathan, Vasanthi S. ;
Ryan, Matthew J. ;
Bole, Dhruv ;
Eaton, John K. ;
Matov, Alexandre ;
Galeas, Jacqueline ;
Dhruv, Harshil D. ;
Berens, Michael E. ;
Schreiber, Stuart L. ;
McCormick, Frank ;
McManus, Michael T. .
NATURE, 2017, 551 (7679) :247-+
[13]   SLC7A11 as a biomarker and therapeutic target in HPV-positive head and neck Squamous Cell Carcinoma [J].
Hemon, Anais ;
Louandre, Christophe ;
Lailler, Claire ;
Godin, Corinne ;
Bottelin, Maxime ;
Morel, Virginie ;
Francois, Catherine ;
Galmiche, Antoine ;
Saidak, Zuzana .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 533 (04) :1083-1087
[14]   Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma [J].
Hu, Kewen ;
Li, Kun ;
Lv, Jing ;
Feng, Jie ;
Chen, Jing ;
Wu, Haigang ;
Cheng, Feixiong ;
Jiang, Wenhao ;
Wang, Jieqiong ;
Pei, Haixiang ;
Chiao, Paul J. ;
Cai, Zhenyu ;
Chen, Yihua ;
Liu, Mingyao ;
Pang, Xiufeng .
JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (04) :1752-1766
[15]   Ferroptosis as a p53-mediated activity during tumour suppression [J].
Jiang, Le ;
Kon, Ning ;
Li, Tongyuan ;
Wang, Shang-Jui ;
Su, Tao ;
Hibshoosh, Hanina ;
Baer, Richard ;
Gu, Wei .
NATURE, 2015, 520 (7545) :57-+
[16]   Designing biomarker studies for head and neck cancer [J].
Kim, Kelly Y. ;
McShane, Lisa M. ;
Conley, Barbara A. .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2014, 36 (07) :1069-1075
[17]   Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma [J].
Kokko, Linda-Lotta ;
Hurme, Saija ;
Maula, Sanna-Mari ;
Alanen, Kalle ;
Grenman, Reidar ;
Kinnunen, Ilpo ;
Ventela, Sami .
ORAL ONCOLOGY, 2011, 47 (06) :510-516
[18]   Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy [J].
Koppula, Pranavi ;
Zhuang, Li ;
Gan, Boyi .
PROTEIN & CELL, 2021, 12 (08) :599-620
[19]   Critical review of the follow-up protocol for head and neck cancer patients [J].
Kyto, E. ;
Haapio, E. ;
Minn, H. ;
Irjala, H. .
JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2019, 133 (05) :424-429
[20]   Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11 [J].
Lang, Xueting ;
Green, Michael D. ;
Wang, Weimin ;
Yu, Jiali ;
Choi, Jae Eun ;
Jiang, Long ;
Liao, Peng ;
Zhou, Jiajia ;
Zhang, Qiang ;
Dow, Ania ;
Saripalli, Anjali L. ;
Kryczek, Ilona ;
Wei, Shuang ;
Szeliga, Wojciech ;
Vatan, Linda ;
Stone, Everett M. ;
Georgiou, George ;
Cieslik, Marcin ;
Wahl, Daniel R. ;
Morgan, Meredith A. ;
Chinnaiyan, Arul M. ;
Lawrence, Theodore S. ;
Zou, Weiping .
CANCER DISCOVERY, 2019, 9 (12) :1673-1685